Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Differentiation of Multiple Myeloma and MGUS by Cross Validated Differential Proteomic Analysis.

Ross D. Brown, PhD, Larissa Belov, PhD, Cris dos Remedios, PhD, Daniel Sze, PhD, Simon Cooper, Mila Dolotin, John Gibson, MD, Douglas E. Joshua, MD

Blood (2006) 108 (11): 3524.

https://doi.org/10.1182/blood.V108.11.3524.3524

Published: 2006

Journal Articles

Gene Expression Profiling of the Clinical Significant CD57 + CD8 + Cytotoxic T Cell Expansions in Patients with Waldenstrom’s Macroglobulinemia.

Daniel Sze, PhD, Tetsuo Yamagishi, BSc, Warren Kaplan, PhD, Ross D. Brown, PhD, Phoebe Joy Ho, MD, John Gibson, MD, Douglas E. Joshua, MD

Blood (2006) 108 (11): 3395.

https://doi.org/10.1182/blood.V108.11.3395.3395

Published: 2006

Journal Articles

Identification and Characterization of Cancer Stem Cells in Multiple Myeloma.

Daniel Sze, PhD, Yen S. Loh, BSc, Suilin Mo, MSc, Warren Kaplan, PhD, Ross D. Brown, PhD, Phoebe Joy Ho, MD, John Gibson, MD, Douglas E. Joshua, MD

Blood (2006) 108 (11): 512.

https://doi.org/10.1182/blood.V108.11.512.512

Published: 2006

Journal Articles

A Pilot Study To Explore the Tolerability and Efficacy of Thalidomide Containing Regimens To Reduce Tumour Cell Load Prior to HSC in Multiple Myeloma and the Feasibility of Harvesting HSC Following Thalidomide Containing Regimens.

Noemi Horvath, MB, ChB, FRACP, FRCPA, Douglas E. Joshua, D. Phil FRACP, John Gibson, MD, Andrew W. Roberts, MBBS, PhD, John Norman, MBBS, FRACP, Craig Underhill, MBBS, FRACP, David M. Ross, MBBS, FRACP, FRCPA, Sonya Stephens, Trevor Rawling, Luen B. To, MD

Blood (2005) 106 (11): 5162.

https://doi.org/10.1182/blood.V106.11.5162.5162

Published: 2005

Journal Articles

The Immunomodulatory Action of Thalidomide in Patients with Multiple Myeloma Involves a Clonal Expansion of Late-Differentiated Cytotoxic Effector Cells.

Ross D. Brown, PhD, Allan Murray, Daniel M. Sze, PhD, Andrew Spencer, MD, Phoebe Joy Ho, MD, John Gibson, MD, Douglas E. Joshua, MD

Blood (2005) 106 (11): 5108.

https://doi.org/10.1182/blood.V106.11.5108.5108

Published: 2005

NARROW

Differentiation of Multiple Myeloma and MGUS by Cross Validated Differential Proteomic Analysis.

Gene Expression Profiling of the Clinical Significant CD57 + CD8 + Cytotoxic T Cell Expansions in Patients with Waldenstrom’s Macroglobulinemia.

Identification and Characterization of Cancer Stem Cells in Multiple Myeloma.

A Pilot Study To Explore the Tolerability and Efficacy of Thalidomide Containing Regimens To Reduce Tumour Cell Load Prior to HSC in Multiple Myeloma and the Feasibility of Harvesting HSC Following Thalidomide Containing Regimens.

The Immunomodulatory Action of Thalidomide in Patients with Multiple Myeloma Involves a Clonal Expansion of Late-Differentiated Cytotoxic Effector Cells.

Email alerts

ASH Publications

American Society of Hematology

Differentiation of Multiple Myeloma and MGUS by Cross Validated Differential Proteomic Analysis.

Gene Expression Profiling of the Clinical Significant CD57 + CD8 + Cytotoxic T Cell Expansions in Patients with Waldenstrom’s Macroglobulinemia.

Identification and Characterization of Cancer Stem Cells in Multiple Myeloma.

A Pilot Study To Explore the Tolerability and Efficacy of Thalidomide Containing Regimens To Reduce Tumour Cell Load Prior to HSC in Multiple Myeloma and the Feasibility of Harvesting HSC Following Thalidomide Containing Regimens.

The Immunomodulatory Action of Thalidomide in Patients with Multiple Myeloma Involves a Clonal Expansion of Late-Differentiated Cytotoxic Effector Cells.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only